Khosrow Kashfi to HT29 Cells
This is a "connection" page, showing publications Khosrow Kashfi has written about HT29 Cells.
Connection Strength
1.063
-
Kodela R, Chattopadhyay M, Vel?zquez-Mart?nez CA, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. Biochem Pharmacol. 2015 Dec 15; 98(4):564-72.
Score: 0.119
-
Kodela R, Nath N, Chattopadhyay M, Nesbitt DE, Vel?zquez-Mart?nez CA, Kashfi K. Hydrogen sulfide-releasing naproxen suppresses colon cancer cell growth and inhibits NF-?B signaling. Drug Des Devel Ther. 2015; 9:4873-82.
Score: 0.118
-
Vannini F, Chattopadhyay M, Kodela R, Rao PPN, Kashfi K. Positional isomerism markedly affects the growth inhibition of colon cancer cells by NOSH-aspirin: COX inhibition and modeling. Redox Biol. 2015 Dec; 6:318-325.
Score: 0.118
-
Vannini F, MacKessack-Leitch AC, Eschbach EK, Chattopadhyay M, Kodela R, Kashfi K. Synthesis and anti-cancer potential of the positional isomers of NOSH-aspirin (NBS-1120) a dual nitric oxide and hydrogen sulfide releasing hybrid. Bioorg Med Chem Lett. 2015 Oct 15; 25(20):4677-82.
Score: 0.118
-
Kodela R, Chattopadhyay M, Goswami S, Gan ZY, Rao PP, Nia KV, Vel?zquez-Mart?nez CA, Kashfi K. Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition. J Pharmacol Exp Ther. 2013 Apr; 345(1):85-94.
Score: 0.099
-
Chattopadhyay M, Kodela R, Olson KR, Kashfi K. NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. Biochem Biophys Res Commun. 2012 Mar 16; 419(3):523-8.
Score: 0.093
-
Chattopadhyay M, Kodela R, Nath N, Street CR, Vel?zquez-Mart?nez CA, Boring D, Kashfi K. Hydrogen sulfide-releasing aspirin modulates xenobiotic metabolizing enzymes in vitro and in vivo. Biochem Pharmacol. 2012 Mar 15; 83(6):733-40.
Score: 0.092
-
Chattopadhyay M, Goswami S, Rodes DB, Kodela R, Velazquez CA, Boring D, Crowell JA, Kashfi K. NO-releasing NSAIDs suppress NF-?B signaling in vitro and in vivo through S-nitrosylation. Cancer Lett. 2010 Dec 08; 298(2):204-11.
Score: 0.083
-
Kashfi K, Rigas B. The mechanism of action of nitric oxide-donating aspirin. Biochem Biophys Res Commun. 2007 Jul 13; 358(4):1096-101.
Score: 0.067
-
Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, Benedini F, Del Soldato P, Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther. 2005 Mar; 312(3):978-88.
Score: 0.056
-
Kaur K, Enders P, Zhu Y, Bratton AF, Powell CR, Kashfi K, Matson JB. Amino acid-based H2S donors: N-thiocarboxyanhydrides that release H2S with innocuous byproducts. Chem Commun (Camb). 2021 Jun 03; 57(45):5522-5525.
Score: 0.044
-
Spiegel A, Hundley TR, Chen J, Gao J, Ouyang N, Liu X, Go MF, Tsioulias GJ, Kashfi K, Rigas B. NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells. Biochem Pharmacol. 2005 Oct 01; 70(7):993-1000.
Score: 0.015
-
Gao J, Kashfi K, Rigas B. In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism. J Pharmacol Exp Ther. 2005 Mar; 312(3):989-97.
Score: 0.014
-
Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, Kalala S, Traganos F, Benardini F, del Soldato P, Kashfi K, Rigas B. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol. 2004 Jun 15; 67(12):2197-205.
Score: 0.014
-
Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, Kashfi K, Rigas B. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res. 2003 Nov 15; 63(22):7613-8.
Score: 0.013